Trexquant Investment LP Arcus Biosciences, Inc. Transaction History

Trexquant Investment LP

  • $8.9 Billion
  • Q3 2025

A detailed history of Trexquant Investment LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 47,593 shares of RCUS stock, worth $955,191. This represents 0.01% of its overall portfolio holdings.

Number of Shares
47,593
Previous 258,937 81.62%
Holding current value
$955,191
Previous $2.11 Million 69.29%
% of portfolio
0.01%
Previous 0.03%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$8.22 - $13.6 $1.74 Million - $2.87 Million
-211,344 Reduced 81.62%
47,593 $647,000
Q2 2025

Aug 12, 2025
BUY
$6.87 - $10.03 $299,332 - $437,017
43,571 Added 20.23%
258,937 $2.11 Million
Q1 2025

May 14, 2025
SELL
$7.85 - $15.24 $668,678 - $1.3 Million
-85,182 Reduced 28.34%
215,366 $1.69 Million
Q4 2024

Feb 12, 2025
BUY
$14.28 - $18.44 $3.04 Million - $3.92 Million
212,552 Added 241.55%
300,548 $4.48 Million
Q3 2024

Nov 12, 2024
SELL
$13.69 - $18.01 $2.25 Million - $2.96 Million
-164,590 Reduced 65.16%
87,996 $1.35 Million
Q2 2024

Aug 13, 2024
BUY
$14.59 - $18.48 $3.13 Million - $3.96 Million
214,469 Added 562.66%
252,586 $3.85 Million
Q1 2024

May 14, 2024
SELL
$14.83 - $20.18 $80,378 - $109,375
-5,420 Reduced 12.45%
38,117 $719,000
Q4 2023

Feb 09, 2024
SELL
$13.43 - $19.63 $471,393 - $689,013
-35,100 Reduced 44.64%
43,537 $831,000
Q3 2023

Nov 13, 2023
BUY
$17.62 - $23.54 $1.39 Million - $1.85 Million
78,637 New
78,637 $1.41 Million
Q1 2023

May 15, 2023
SELL
$15.96 - $23.15 $99,654 - $144,548
-6,244 Reduced 24.91%
18,827 $343,000
Q4 2022

Feb 13, 2023
BUY
$19.7 - $35.71 $493,898 - $895,285
25,071 New
25,071 $518,000
Q2 2022

Aug 11, 2022
BUY
$17.23 - $37.73 $141,113 - $309,008
8,190 New
8,190 $208,000
Q2 2021

Aug 12, 2021
SELL
$22.75 - $35.77 $163,549 - $257,150
-7,189 Closed
0 $0
Q1 2021

May 13, 2021
SELL
$26.16 - $41.39 $163,133 - $258,108
-6,236 Reduced 46.45%
7,189 $202,000
Q4 2020

Feb 11, 2021
SELL
$17.0 - $32.36 $667,267 - $1.27 Million
-39,251 Reduced 74.51%
13,425 $349,000
Q3 2020

Nov 06, 2020
BUY
$17.14 - $25.47 $399,824 - $594,138
23,327 Added 79.48%
52,676 $903,000
Q2 2020

Aug 07, 2020
BUY
$13.97 - $36.56 $42,468 - $111,142
3,040 Added 11.55%
29,349 $726,000
Q1 2020

May 08, 2020
BUY
$8.78 - $19.28 $230,993 - $507,237
26,309 New
26,309 $365,000
Q2 2019

Aug 09, 2019
SELL
$7.29 - $13.38 $119,271 - $218,910
-16,361 Closed
0 $0
Q1 2019

May 13, 2019
BUY
$8.95 - $12.49 $146,430 - $204,348
16,361 New
16,361 $204,000

Others Institutions Holding RCUS

# of Institutions
212
Shares Held
67.7M
Call Options Held
3.3M
Put Options Held
146K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.45B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email